29 results about "Extracellular proteins" patented technology

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

To provide bifunctional compounds that can be used to promote or enhance the degradation of certain circulating proteins.SOLUTION: What is claimed is: A compound comprising Formula (I): [Ab] k' - [CON] h - [Linker] I - [CON] h' - [CRBM] j' (I) wherein: Ab is an antibody that binds to an extracellular protein; CRBM is a cell receptor binding moiety that binds to at least one receptor on the surface of a degradative cell in a subject; (I) thereby results in endocytosis and degradation of the extracellular protein; each CON is independently a bond or a group that covalently links the Ab to the CRBM, the Ab to the linker, and / or the linker to the CRBM; the linker is a group having a valence ranging from 1 to 15; k ' is an integer ranging from 1 to 15; h is an integer ranging from 0 to 15; I is an integer ranging from 0 to 15; h ' is an integer ranging from 0 to 15; and j is an integer ranging from 1 to 15.SELECTED DRAWING: Figure 1

Extracellular protein degraders and compositions with improved pharmacokinetic properties are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selective degradation of the Target Extracellular Protein, for example immunoglobulin in vivo to treat disorders mediated by the extracellular protein.

The invention discloses a method for secretory expression of recombinant mechanical structural protein by using escherichia coli and application, and relates to the field of bioengineering. According to the method, signal peptides are introduced to the N end of recombinant mechanical structural proteins, and the signal peptides, namely OmpA, PelB, PhoA, DsbA and STII, capable of guiding different recombinant mechanical structural proteins to secrete and express are screened from six natural signal peptides from escherichia coli and other species. Meanwhile, the yield of extracellular protein is further improved by combining an amino acid tRNA supplement strategy. According to the method, the recombinant escherichia coli strain capable of efficiently secreting and expressing the mechanical structure protein can be obtained, the downstream purification process is simplified, and the method has important application value.

The invention provides a mammal protein efficient expression system based on a prokaryotic two-component signal transduction system (TCS, two-component system) and application of the mammal protein efficient expression system, and the mammal protein efficient expression system comprises the TCS capable of efficiently recruiting transcription factors and a carrier capable of being induced by the TCS to express a target gene. By transfecting mammalian cells with the system, a protein of interest can be produced in the cells or extracellular proteins can be produced in a secreted form. Based on the mammal protein high-efficiency expression system provided by the invention, stable and high-level expression of the target protein can be realized. The invention provides a new method for production of therapeutic proteins and antibodies, provides key technical support for preparation of mammalian protein samples in the research fields of structural biology and the like, and has important scientific significance for development of life science, diagnosis and treatment of diseases and research and development of medicines.

The present disclosure relates to novel nucleic acids for immune cell adapters, comprising a ribonucleic acid of formula I: R1-SP-R2-R3-R4-R5 (I) wherein R1 is a 5'non-transcriptional region (UTR); sP encodes a signal peptide; r2 encodes a first single chain variable fragment (scFv) that binds to a first extracellular protein or a heavy chain variable region (VH only) that binds to a first extracellular protein; r3 encodes a second scFv that binds to a second extracellular protein; r4 encodes a half-life extender; r < 5 > is 3 'UTR wherein R < 1 > to R < 5 > are in the 5' to 3 'direction for use in the treatment of cancer, including but not limited to hematological cancers, including multiple myeloma.

This invention relates to the field of microbial technology, specifically to a method for the production and extraction of N-acetylmuroic acid-L-alanine amidase via microbial fermentation. The method for preparing N-acetylmuroic acid-L-alanine amidase provided by this invention utilizes *Clostridium beijerinckii* XH0906 for fermentation to produce N-acetylmuroic acid-L-alanine amidase. As the main extracellular protein of this bacterium, N-acetylmuroic acid-L-alanine amidase has a high yield and is beneficial for subsequent separation and purification. This method has advantages such as simplicity, efficiency, and low cost, providing an effective method for the preparation of N-acetylmuroic acid-L-alanine amidase, and has good application prospects in the fields of microbial food, biomedicine, and antibacterial applications.

This invention discloses a protease-responsive GPCR receptor and its applications. The protease-responsive GPCR receptor of this invention comprises an extracellular protease recognition domain, a transmembrane domain, and an intracellular signaling domain; the extracellular protease recognition domain contains a peptide hydrolyzed by the protease; the intracellular signaling domain contains an HCV enzyme hydrolyzed peptide, a nuclear localization sequence (NLS), a Cas protease, and a coupled nuclear transcription factor. This protease-responsive GPCR receptor can induce endogenous dCas9 assembly into the nucleus and activate the chimeric antigen receptor signaling pathway in natural killer cells in response to extracellular proteases, providing a new solution for developing novel precision immunotherapy.

The application discloses a method for treating antibiotic wastewater by using high-concentration ammonia-nitrogen wastewater and application thereof, and belongs to the technical field of purification treatment. The method is characterized in that: microalgae cells cultured to the logarithmic phase are inoculated into sterilized high-concentration ammonia-nitrogen wastewater for culture, and then the microalgae cells are used for treating antibiotic wastewater. The method provided by the application has remarkable economic benefits, and the microalgae are widely distributed in nature, so that no additional carbon source is needed, and the cost is low. Moreover, more extracellular proteins are secreted by using high-concentration ammonia-nitrogen, and the microalgae remove the antibiotics while achieving the purpose of treating ammonia-nitrogen.

This invention discloses a method for efficiently extracting and enriching sludge-based antimicrobial peptides from activated sludge, belonging to the field of activated sludge resource recycling and utilization. The invention removes impurities from the activated sludge by releasing intracellular and extracellular proteins through low-temperature hot alkaline hydrolysis, followed by enzymatic hydrolysis with proteases to obtain a crude extract containing peptides of different molecular weights. Further purification involves primary purification to remove impurities and secondary purification to separate amino acids and peptides from the organic matter mixture, yielding purified antimicrobial peptide products of different molecular weights. Antimicrobial activity is assessed using an inhibition zone assay, resulting in a highly effective antimicrobial sludge-based antimicrobial peptide molecular template. This template is used to prepare a magnetic molecularly imprinted polymer (Fe3O4@MIPs). Fe3O4@MIPs are then used to adsorb and enrich the highly effective antimicrobial sludge-based antimicrobial peptides in the crude extract. After elution with an eluent, highly effective antimicrobial sludge-based antimicrobial peptides are obtained.

The invention discloses lactobacillus gasseri BSJM25L011, lactobacillus gasseri extracellular protein with an oil control effect as well as a preparation method and application of the lactobacillus gasseri extracellular protein. The lactobacillus gasseri has the taxonomic name of Lactobacillus gasseri, is preserved in the China General Microbiological Culture Collection Center on June 16, 2025, has the preservation number of CGMCC No.34898, has the preservation address of No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and has the postcode of 100101, and the lactobacillus gasseri extracellular protein with the oil control effect is obtained by fermenting and culturing the lactobacillus gasseri strain BSJM25L011. The lactobacillus gasseri BSJM25L011 can generate a novel, mild and efficient natural biological oil control active component, and the lactobacillus gasseri extracellular protein disclosed by the invention has an excellent oil control effect, can remarkably regulate skin sebum secretion, can be widely applied to the field of oil control skin external preparations, expands the application field of the lactobacillus gasseri, and has a good application prospect. And the use safety is high.

Compounds and compositions that have a Mannose 6-Phosphate Receptor Ligand bound to an Extracellular Protein Binding Ligand are provided for the selective degradation of a target extracellular protein in vivo to treat disorders mediated by the extracellular protein.

The present application belongs to the field of agricultural biotechnology, and through a large number of sequence analysis and tests, a short peptide with a function of antagonizing fungi in an extracellular protein Atp2 beta subunit protein of Rhodopseudomonas palustris is found. Tests show that the short peptide with the function of antagonizing fungi has low production cost, is non-toxic and environmentally friendly, can significantly inhibit the formation of appressorium of rice blast fungus and the pathogenicity on the host, and has potential broad-spectrum antagonistic function activity.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions are described that have an asialoglycoprotein receptor (ASGPR) binding ligand conjugated to an extracellular protein binding ligand that selectively degrades target extracellular proteins in vivo to treat disorders mediated by the extracellular proteins.

The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and / or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

The invention discloses a method for improving extracellular protein yield and hemicellulase activity of filamentous fungi, and belongs to the field of gene engineering. According to the method, production of extracellular protein and hemicellulase of filamentous fungi is improved by knocking out or mutating a part of basic groups of a transcription factor or weakening expression of the transcription factor, and a transcription factor coding gene is NCU04001. The recombinant bacteria obtained by knocking out or mutating partial bases or weakening filamentous fungus transcription factor gene expression can be applied to degrading cellulose or improving cellulase expression or expression of other extracellular proteins.

The invention discloses a method for improving extracellular protein yield and cellulase activity of filamentous fungi and application, and belongs to the field of gene engineering. According to the method, production of extracellular protein and cellulase of filamentous fungi is improved by knocking out or mutating a part of basic groups of a transcription factor NCU03489 or weakening expression of the transcription factor. The recombinant bacteria obtained by knocking out or partially mutating basic groups or weakening the expression of the filamentous fungus transcription factor NCU03489 gene can be applied to degrading cellulose or improving the expression quantity of cellulase or other proteins.

The application discloses a penicillium oxalicum engineering bacterium and a construction method thereof. Penicillium oxalicum The engineering bacterium is named penicillium oxalicum (QL-ACxrC-ACreA) and has a preservation number of CCTCC NO: M 2026896. The penicillium oxalicum engineering bacterium is obtained by knocking out transcriptional inhibitor CxrC and transcriptional factor CreA of carbon catabolite repression of filamentous fungi, so that when starch is used as the only carbon source for fermentation, the amylase activity and extracellular protein content generated by the penicillium oxalicum engineering bacterium are significantly improved; and the knocking out of the two factors synergistically improves the starting efficiency of the promoter Pamy15A.

The invention provides a strain composite system evolution method and application thereof in production of microbial protein. A strain composite system composed of filamentous fungi and saccharomycetes is subjected to secondary inoculation and passage in a mixed fermentation corncob system. Through strain domestication and culture and passage under specific conditions, synergistic metabolism among cells under a co-culture condition is improved, so that the degradation capacity of lignocellulose of a strain composite system and the accumulation capacity of strain protein are improved. Compared with the prior art, the method has the advantages that the tedious passage operation and the long domestication period of a flat plate are reduced, the lignocellulose corncob is directly adopted as a carbon source for flora domestication, the conversion and utilization process is simplified, and the tank fermentation effect of a domesticated strain composite system is remarkably improved; the content of true protein, the average degradation rate of cellulose and the like, the accumulation amount of yeast, the dry weight of thalli, the content of extracellular protein and the like are improved to different degrees.

The invention relates to application of endosomal membrane labeled nanoparticles in targeted degradation of extracellular proteins, and belongs to the technical field of nano biological medicines. The endosomal membrane labeled nanoparticle provided by the invention takes a high-molecular organic material as a carrier, the surface of the endosomal membrane labeled nanoparticle is modified with extracellular protein targeting peptide and endosomal anchoring phagosome targeting peptide consisting of endosomal membrane insertion polypeptide and phagosome targeting peptide, and the constructed nanoparticle can specifically recognize extracellular target protein, so that the endosomal membrane labeled nanoparticle has the advantages of high specificity and high specificity. According to the present invention, the target protein enters the endosome through the endocytosis mechanism of the target protein, the membrane insertion polypeptide is inserted into the endosome lipid membrane, the phagosome targeting peptide at the terminal is anchored on the endosome surface, the cytoplasm phagosome is recruited to perform phagocytosis, and finally the target protein is degraded through the endosome-phagosome-lysosome approach; the preparation method of the endosomal membrane labeled nanoparticles is simple and convenient, and the endosomal membrane labeled nanoparticles have good biological safety and efficient delivery capacity and have huge potential in the fields of biomedical research and clinical treatment.

The invention relates to the technical field of biology, and provides a targeted protein degradation method. The method comprises the following steps: carrying out first incubation treatment on a biological sample and an enzyme-labeled antibody to obtain a first incubation product; and carrying out second incubation treatment on the first incubation product and a labeled substrate to realize degradation of the target protein in the biological sample. Therefore, compared with the traditional antibody-based degradation agent, the targeted protein degradation method disclosed by the invention can directly use the commercially available antibody, and does not need complex antibody engineering modification or chemical modification. By labeling adjacent to the target protein, efficient degradation can be realized, and the method is applicable to both intracellular protein and extracellular protein (including membrane protein and secretory protein). The method not only simplifies the experimental process, reduces the cost, but also improves the flexibility and universality of operation, and has application potential and value in the fields of biological coupling and biological medicine.

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and / or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

The present application relates to the technical field of biological medicine. The present application provides a kind of targeted degradation protein and its application, the amino acid sequence of the targeted degradation protein is as shown in SEQ ID NO.3.The targeted degradation protein of the present application can actively mediate the endocytosis and degradation process of target protein based on extracellular protein targeted degradation technology, reduce the abundance of target protein from the source, so as to more fundamentally weaken its biological effect. Only need to screen or develop the binding molecule with high affinity to target protein, it can trigger its degradation. Significantly reduce the design difficulty, and greatly expand the range of target protein that can be intervened.

Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. Fully genetically-encodable lysosome-targeting chimeras (GELYTAC) are provided, which allows for example integration into therapeutic cells for targeted delivery at diseased sites. The glycopeptide portion of LYTACs was replaced with the protein insulin like growth factor 2 (IGF2). After showing initial efficacy with wild type IGF2, the potency of GELYTAC was improved by mutation, resulting in an engineered GELYTAC construct that can secrete from cells, including from human primary T-cells, to drive the uptake of various targets into receiver cells.

The invention relates to the field of sewage treatment, in particular to a treatment method for secondary sedimentation tank float sludge initiated by a DCM control agent in sulfate pulping. The method comprises a step of adding a fusion protein as shown in SEQ ID NO.3 into a secondary sedimentation tank, and further comprises the following steps: regulating the concentration of dissolved oxygen to 2.0-4.0 mg / L, the temperature to 35-40 DEG C and the pH value to 6.8-7.2, hydrolyzing extracellular proteins or extracellular polysaccharides generated by various zoogloea bacteria in the secondary sedimentation tank, destroying a foam skeleton and reducing adhesion of microhyphae, thereby realizing the purpose of removing the microhyphae in the secondary sedimentation tank. And the problem of'combined action of a DCM control agent and filamentous bacteria 'is solved, and the problem of float sludge in a secondary sedimentation tank is solved.

The present disclosure relates to novel nucleic acids for an immune cell engagers, comprising a ribonucleic acid of formula I: R1 – SP – R2 – R3 – R4 – R5 (I), where R1 is a 5' untranslated region (UTR); SP encodes a signal peptide; R2 encodes a first single chain variable fragment (scFv) that binds a first extracellular protein or a variable region of a heavy chain (VH-only) that binds a first extracellular protein; R3 encodes a second scFv that binds a second extracellular protein; R4 encodes a half-life extender; R5 is a 3'UTR, and where R1 to R5 are oriented 5' to 3', for the treatment of cancers, including but not limited to hematological cancers, including multiple myeloma.